This $3 Biotech Could Be Worth $11.45, Analyst Says

Perspective Therapeutics Inc. (NYSE: CATX) could benefit from growing interest in radiopharmaceutical cancer treatments, according to William Blair. The firm on Friday initiated coverage on Perspective, noting the company is well positioned to leverage lead-212-based radiopharmaceuticals with its peptide platform and established supply chain.

Perspective has designed its platform for increased tolerability and is positioned to be a leader in the radiopharmaceutical industry from a therapeutic perspective. William Blair initiated coverage with an Outperform rating. Analyst Andy Hsieh wrote on Friday that advances in complex manufacturing and supply-chain logistics, growing acceptance of radiopharmaceuticals, established regulatory precedent, an expanding network of...